Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FAWEL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,163
Award facts
- Contract value 100% obligated
- $17,163.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a firm fixed-price ceiling value of $17,163.06. The order is scheduled for ultimate completion by August 29, 2025, with performance taking place in Conshohocken, Pennsylvania. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned small business. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, making it a critical pharmaceutical product for Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables firm fixed-price orders for comprehensive pharmaceutical supplies supporting military health facilities worldwide. As a pharmaceutical wholesaler based in Park Ridge, Illinois, DMS Pharmaceutical Group has established itself as a key supplier within the federal pharmaceutical supply chain, providing branded and generic prescription drugs, biologics, and medical consumables to Defense Department healthcare sites. The company's extensive contract portfolio demonstrates consistent success in delivering specialized pharmaceutical products ranging from oncology treatments to vaccines and specialty medications to military medical facilities across the nation.
Quick answers
Who was awarded contract SPE2DB25FAWEL?
SPE2DB25FAWEL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 28, 2025.
How much is contract SPE2DB25FAWEL worth?
The government has obligated $17,163 on SPE2DB25FAWEL.
Is contract SPE2DB25FAWEL an order under another contract?
Yes. SPE2DB25FAWEL is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAWEL competed?
The extent of competition for SPE2DB25FAWEL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award